InflaRx N.V.IFRX
Price (close)
$1.93
Market cap
$284.4M
P/E
—
Revenue (FY)
$29,331
Net income
-$45.6M
Dividend yield
—
1-year total return
49.6%
Net margin
-155582.0%
Revenue growth
-82.3%
Debt / equity
—
What InflaRx N.V. does.
proprietary technologies to discover, develop and commercialize first-in-class, highly potent and specific inhibitors of the complement
activation factor known as C5a and its receptor C5aR. The complement system is an integral part of the innate immune system and protects
the body, for example by recognizing and removing bacteria, viruses, and other infectious agents, collectively referred to as pathogens.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | -$32.2M | $63,089 | $165,789 | $29,331 |
| Net income | -$34.0M | -$45.6M | -$29.5M | -$42.7M | -$46.1M | -$45.6M |
More on IFRX.
- InflaRx N.V. summary
- InflaRx N.V. financial statements
- InflaRx N.V. key metrics
- InflaRx N.V. health scores and style box
- InflaRx N.V. earnings
- InflaRx N.V. dividends
- InflaRx N.V. valuation
- InflaRx N.V. ownership and insiders
- InflaRx N.V. peers
Figures from InflaRx N.V.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.